Investigating long-term complications of COVID-19 on lungs, heart, and kidneys

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to understand the incidence of pulmonary, cardiovascular, and renal complications that may arise after the acute phase of COVID-19. It will involve collecting blood samples, conducting physical tests like the six-minute walk test, and utilizing imaging techniques such as HRCT and heart ultrasounds to assess organ function. The study will compare individuals with a history of COVID-19 to those without, focusing on the long-term effects of the virus on organ health. The goal is to gather detailed knowledge that can inform clinical guidelines and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Group A (comparators)

1. Adults (18 years or more) of both genders
2. Negative history of acute COVID-19

Group B (patients with ΝΟ dysfunction)

1. Adults (18 years or more) of both genders
2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
3. Absence of any current overt organ dysfunction
4. Absence of signs of any organ dysfunction during acute COVID-19

Group C (patients with dysfunctions)

1. Adults (18 years or more) of both genders
2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19

Exclusion Criteria:

Group A (comparators)

1. Any other co-existing disorder generating clinical symptoms
2. Failure to thrive according to the attending physicians
3. Pregnancy or lactation

Group B (patients with ΝΟ dysfunction)

1. Any other co-existing disorder generating clinical symptoms
2. Failure to thrive according to the attending physicians
3. Pregnancy or lactation

Group C (patients with dysfunctions)

1. Any other co-existing disorder generating clinical symptoms
2. Medical history of any of:

   * stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria
   * pulmonary fibrosis or pulmonary hypertension
   * stage IV solid tumour malignancy under chemotherapy or radiotherapy
   * systemic sclerosis
   * congestive heart failure
   * stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians
4. Pregnancy or lactation

Where it's running

• 10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
  Athens, Greece Recruiting
• 4th Department of Internal Medicine, ATTIKON University General Hospital
  Athens, Greece Recruiting
• Obstructive Diseases Clinic, Sotiria Athens Hospital of Chest Diseases
  Athens, Greece Recruiting
• Out-patient department of Infectious Diseases, Sotiria Athens Hospital of Chest Diseases
  Athens, Greece Recruiting
• 1st Department of Internal Medicine, Thriasio General Hospital of Elefsina
  Elefsina, Greece Recruiting
• 2nd Department of Internal Medicine, Thriasio General Hospital of Elefsina
  Elefsina, Greece Recruiting

Study contacts

• Study coordinator: Prof. Evangelos Giamarellos-Bourboulis
• Email: egiamarel@med.uoa.gr
• Phone: 00302105831994

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.